Merck KGaA's Stimuvax shows mild AEs with up to 8.2 years of use

Extended follow-up data from a randomized Phase IIb study of patients with inoperable advanced non-small cell lung cancer receiving Merck  KGaA's Stimuvax (BLP25 liposome vaccine) have shown that the most common  treatment-related adverse events observed after up to 8.2 years of  treatment with the immuno-stimulator were mild injection site reactions  and nausea.

This long-term analysis presented at ASCO investigated the use of  Stimuvax in 16 patients (median age 57.5 years) who received prolonged  treatment for between 2.0 and 8.2 years. Of these, 10 have been treated  for more than five years and eight are still receiving it. Injection  site reactions decreased with treatment duration and there was no  evidence of serious treatment-related adverse events or autoimmune  reactions with prolonged exposure.